Possible common central pathway for resistin and insulin in regulating food intake.
OBJECTIVE
Adipose tissue has been the object of intense research in the field of obesity and diabetes diseases in the last decade. Examination of adipocyte-secreted peptides led to the identification of a unique polypeptide, resistin (RSTN), which has been suggested as a link between obesity and diabetes. RSTN plays a clearly documented role in blocking insulin (INS)-induced hypoglycaemia. As brain injection of INS affects feeding behaviour, we studied the possible interaction between INS and RSTN in food-deprived rats, measuring effects on food intake. In addition, we examined how RSTN might affect neuropeptide Y (NPY)-induced feeding, as studies have shown that rat RSTN can interfere with the NPY system.


METHODS
Overnight food-deprived rats were injected into the third brain ventricle (3V) with either INS (10 or 20 mUI), RSTN (0.1-0.4 nmol/rat), or saline before access to food. Another group of rats was injected into the 3V with RSTN alone, NPY alone or RSTN plus NPY. Their food intake and body weight were measured.


RESULTS
Our results confirm the hypophagic effect of RSTN on food deprivation-induced food intake, and more importantly, show that RSTN neither potentiates nor blocks the effects of INS on food intake, but does reduce the hyperphagic effect of NPY.


CONCLUSIONS
The observation that RSTN does not modify feeding INS-induced hypophagia, but does influence NPY-induced feeding, points to the possibility that RSTN may be involved in control of food intake through an NPY-ergic mechanism as INS.
Cifani
C
C
Department of Experimental Medicine and Public Health, University of Camerino, 62032 Camerino, Italy.
Durocher
Y
Y
Pathak
A
A
Penicaud
L
L
Smih
F
F
Massi
M
M
Rouet
P
P
Polidori
C
C
D000273:Adipose Tissue / Q000378:metabolism / Q000503:physiopathology; D000818:Animals; D001069:Appetite Regulation / Q000187:drug effects / Q000502:physiology*; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006963:Hyperphagia / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D007276:Injections, Intraventricular; D007328:Insulin / Q000008:administration & dosage / Q000378:metabolism*; D008297:Male; D053858:Metabolic Networks and Pathways; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000378:metabolism; D009765:Obesity / Q000150:complications / Q000378:metabolism / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D052243:Resistin / Q000008:administration & dosage / Q000378:metabolism*
D007328:Insulin; D009478:Neuropeptide Y; D052243:Resistin